PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

BRAF inhibitors (BRAFi) selectively target oncogenic BRAF(V600E/K) and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy. Better characterization of the underlying molecular proce...

Descripción completa

Detalles Bibliográficos
Autores principales: Vidarsdottir, Linda, Azimi, Alireza, Das, Ishani, Sigvaldadottir, Ingibjorg, Suryo Rahmanto, Aldwin, Petri, Andreas, Kauppinen, Sakari, Ingvar, Christian, Jönsson, Göran, Olsson, Håkan, Frostvik Stolt, Marianne, Tuominen, Rainer, Sangfelt, Olle, Pokrovskaja Tamm, Katja, Hansson, Johan, Grandér, Dan, Egyházi Brage, Suzanne, Johnsson, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155038/
https://www.ncbi.nlm.nih.gov/pubmed/34040017
http://dx.doi.org/10.1038/s41598-021-89389-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155038/
https://www.ncbi.nlm.nih.gov/pubmed/34040017
http://dx.doi.org/10.1038/s41598-021-89389-9

Ejemplares similares